ABOUT

Attention Deficit Hyperactivity Disorder (ADHD)

VYVANSE is indicated for the treatment of ADHD. Treatment should be commenced by a specialist.1

A diagnosis of ADHD implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before 12 years of age.1

Binge Eating Disorder (BED)

VYVANSE is indicated for the treatment of moderate to severe BED in adults when non-pharmacological treatment is unsuccessful or unavailable. Treatment should be commenced and managed by a psychiatrist.1

Product Alert: Two minor typographical errors have been identified on the current VYVANSE packaging. These errors do not impact the quality of the capsules or patient safety. Patients should continue to take their medication as prescribed. More information is available on the TGA Website.

Useful resources
icon
Title card
HCP GUIDE TO MANAGING ADHD PATIENTS WITH VYVANSE
icon
Title card
PRODRUG STIMULANT BOOKLET
icon
Title card
DOSE AND ADMINISTRATION GUIDE

PBS Information: This product is listed on the PBS. Authority required. Refer to PBS Schedule for full authority information.

Click here to review the full Product Information before prescribing.

  1. VYVANSE® (lisdexamfetamine dimesilate) Approved Product Information.

You are now leaving the TakedaPro website

This link opens a website that is not operated by Takeda. We are not responsible for the content or availability of linked websites.

Cancel

Continue